» Articles » PMID: 21553639

Generating Sociability to Drive Science: Patient Advocacy Organizations and Genetics Research

Overview
Journal Soc Stud Sci
Publisher Sage Publications
Specialty Science
Date 2011 May 11
PMID 21553639
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

This paper examines how patient advocacy organizations (PAOs) representing those with rare genetic disorders drive research to their concerns. The rarity of the diseases produces a basic condition of marginalization: small numbers of widely distributed disease sufferers. The lack of promise of an eventual market makes it difficult to attract the economic and biological resources necessary for sustained research. My analysis relies mainly on 21 interviews with leaders from nine PAOs and scientists involved with them, and seeks to understand how PAOs try to attract and influence scientific research. Using a comparative framework, I find that the five main mechanisms emphasized in the literature--economic resources, social movement-style mobilization, moving early, lay expertise, and organizational controls--cannot fully explain the differences in strategies and relationships among members of my PAO sample. I propose instead to show how 'sociability'--forging close relationships with scientists and orchestrating relationships among them--enables PAOs to drive research to their concerns. I show how the strategic manipulation of sociability can give PAOs substantial influence over the research process. However, the forms of sociability that yield the greatest effects are difficult to achieve, and most forms of relationship-building offer PAOs much less influence on research.

Citing Articles

'Advocacy groups are the connectors': Experiences and contributions of rare disease patient organization leaders in advanced neurotherapeutics.

Nguyen C, Kariyawasam D, Alba-Concepcion K, Grattan S, Hetherington K, Wakefield C Health Expect. 2022; 25(6):3175-3191.

PMID: 36307981 PMC: 9700154. DOI: 10.1111/hex.13625.


Building Research Initiatives by Developing Group Effort (BRIDGE): Patient-Partners in Aphasia Research.

Brice A, Hinckley J Semin Speech Lang. 2022; 43(5):426-444.

PMID: 36288736 PMC: 9605818. DOI: 10.1055/s-0042-1756644.


The involvement of rare disease patient organisations in therapeutic innovation across rare paediatric neurological conditions: a narrative review.

Nguyen C, Alba-Concepcion K, Palmer E, Scully J, Millis N, Farrar M Orphanet J Rare Dis. 2022; 17(1):167.

PMID: 35436886 PMC: 9014615. DOI: 10.1186/s13023-022-02317-6.


Ethical challenges for a new generation of early-phase pediatric gene therapy trials.

Iyer A, Saade D, Bharucha-Goebel D, Foley A, Averion G, Paredes E Genet Med. 2021; 23(11):2057-2066.

PMID: 34234300 DOI: 10.1038/s41436-021-01245-3.


Stigma and psychological distress among pediatric participants in the FD/MAS Alliance Patient Registry.

Konradi A BMC Pediatr. 2021; 21(1):173.

PMID: 33853566 PMC: 8048182. DOI: 10.1186/s12887-021-02647-7.